ANTWERP, Belgium and TOKYO, May 30, 2017 /PRNewswire/ --
genae, a global ContractResearch Organization (CRO) and service provider for the medical industries, announced the closing of an investment in Meditrix. The clinical research group further obtained a call option to acquire all remaining shares of Meditrix.
"While Japan represents a key market for the medical industries, it is a complex system for foreign med-tech companies to penetrate" said Bart Segers, genae's CEO. "Having a clear understanding of the regulatory and market hurdles is critical to decrease time and cost to market, and to avoid hazardous strategies for our customers".
"Medical therapeutics and the medical device industries in Japan will benefit from the strategic partnership between genae and Meditrix," according to Ichiro Oshiba, President of Meditrix. "This collaboration will accelerate the much-required adoption of sophisticated medical technologies that are being developed outside Japan", he continued. "In addition, it presents a unique window for the promotion of the Japanese medtech industries".
With this investment, genae further expands its activities in Japan and in the Asia Pacific region.
About the genae group
genae is involved in the development and commercialization of medical devices that change medical practice. genae is a full service CRO and service provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. With HQ in Antwerp, Belgium, genae operates from 11 offices in 9 countries and serves a client base ranging from publicly traded, strategic players to very early start-ups.
Please visit www.genae.com
Meditrix is a full service CRO with focus on clinical studies of medical devices in pre- and post-marketing stage in Japan. In such activities, Meditrix is contributing to collecting clinical data by utilizing its well-trained resources and its proprietary Electronic Data Capture system, tailored for the Japanese market. Meditrix operates from its HQ in Tokyo and from branch offices in Osaka and Fukuoka.
Please visit http://meditrix.jp
Contact genae associates nv Bart Segers, CEO +32 3 290 03 06 Justitiestraat 6B, 2018 Antwerp, Belgium [email protected] Meditrix Co., Ltd. Ichiro Oshiba, President +81 3 6261 5111 1-5-15 Hirakawa-cho, Chiyoda-ku, Tokyo, Japan [email protected]
Subscribe to our Free Newsletters!
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it ...
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...View All